

Referencias.

- Roubille C, Haraoui B. Interstitial lung diseases induced or exacerbated by DMARDs and biologic agents in rheumatoid arthritis: a systematic literature review. *Semin Arthritis Rheum.* 2014;43(5):613-26.
- Nakashita T, Ando K, Kaneko N, Takahashi K, Motojima S. Potential risk of TNF inhibitors on the progression of interstitial lung disease in patients with rheumatoid arthritis. *BMJ Open.* 2014;4(8):e005615.
- Koo BS, Hong S, Kim YJ, Kim YG, Lee CK, Yoo B. Mortality in patients with rheumatoid arthritis-associated interstitial lung disease treated with an anti-tumor necrosis factor agent. *Korean Journal of Internal Medicine.* 2015;30(1):104-9.
- Mera-Varela A, Perez-Pampin E. Abatacept therapy in rheumatoid arthritis with interstitial lung disease. *J Clin Rheumatol.* 2014;20(8):445-6.
- Akiyama M, Kaneko Y, Yamaoka K, Kondo H, Takeuchi T. Association of disease activity with acute exacerbation of interstitial lung disease during tocilizumab treatment in patients with rheumatoid arthritis: a retrospective, case-control study. *Rheumatol Int.* 2016;36(6):881-9.
- Chartrand S, Swigris JJ, Peykova L, Fischer A. Rituximab for the treatment of connective tissue disease-associated interstitial lung disease. *Sarcoidosis Vasc Diffuse Lung Dis.* 2015;32(4):296-304.
- Jani M, Hirani N, Matteson EL, Dixon WG. The safety of biologic therapies in RA-associated interstitial lung disease. *Nat Rev Rheumatol.* 2014;10(5):284-94.
- Perez-Alvarez R, Perez-de-Lis M, Diaz-Lagares C, Pego-Reigosa JM, Retamozo S, Bove A, et al. Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. *Semin Arthritis Rheum.* 2011;41(2):256-64.
- Hadjinicolaou AV, Nisar MK, Bhagat S, Parfrey H, Chilvers ER, Ostor AJ. Non-infectious pulmonary complications of newer biological agents for rheumatic diseases--a systematic literature review. *Rheumatology (Oxford).* 2011;50(12):2297-305.
- Dixon WG, Hyrich KL, Watson KD, Lunt M, Symmons DP. Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register. *Ann Rheum Dis.* 2010;69(6):1086-91.
- Yousem SA, Dacic S. Pulmonary lymphohistiocytic reactions temporally related to etanercept therapy. *Mod Pathol.* 2005;18(5):651-5.
- Gifre L, Ruiz-Esquide V, Xaubet A, Gomez-Puerta JA, Hernandez MV, Sanmarti R. Lung sarcoidosis induced by TNF antagonists in rheumatoid arthritis: a case presentation and a literature review. *Arch Bronconeumol.* 2011;47(4):208-12.
- Herrinton LJ, Harrold LR, Liu L, Raebel MA, Taharka A, Winthrop KL, et al. Association between anti-TNF-alpha therapy and interstitial lung disease. *Pharmacoepidemiol Drug Saf.* 2013;22(4):394-402.
- Curtis JR, Sarsour K, Napalkov P, Costa LA, Schulman KL. Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor alpha agents, a retrospective cohort study. *Arthritis Res Ther.* 2015;17:319.

García-Vicuña R OA, Carmona L, Ibañez M, Castrejón I, Laffón A. Inflammatory interstitial lung disease in rheumatoid arthritis patients treated with biologic treatment. Incidence and mortality rates compared with patients non receiving biologics [Abstract]. *Ann Rheum Dis* 2005; 64 (Suppl (III)):470.

Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, et al. Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan. *J Rheumatol*. 2014;41(1):15-23.

E. Matteson TB, J. Ryu, C. Crowson, T. Hartman and P. Dellaripa, . "Open-Label, Pilot Study of the Safety and Clinical Effects of Rituximab in Patients with Rheumatoid Arthritis-Associated Interstitial Pneumonia," *Open Journal of Rheumatology and Autoimmune Diseases*, Vol. 2 No. 3, 2012, pp. 53-58. .

Narváez J RM, Alegre JJ, Albert Espí G, Gómez Vaquero C, Borrell H, et al. . Rituximab efficacy in the treatment of diffuse interstitial lung disease associated with rheumatoid arthritis [abstract]. *Arthritis Rheum* 2015;67 (Suppl S10):1569.

Becerra E CG, Leandro M. . Safety and efficacy of rituximab in patients with rheumatoid arthritis and lung involvement [Abstract]. *Ann Rheum Dis* 2013;72(Suppl. 3):450.

Dass S AF, Vital E, Bingham S, Buch M, Beirne P, et al. . Safety of rituximab in patients with rheumatoid arthritis and concomitant lung disease. *Ann Rheum Dis* 2011;70(Suppl. 3):71.

Dogu B, Atilla N, Cetin GY, Yilmaz N, Oksuz H. A case of acute respiratory failure in a rheumatoid arthritis patient after the administration of abatacept. *Eur J Rheumatol*. 2016;3(3):134-5.

Wada T, Akiyama Y, Yokota K, Sato K, Funakubo Y, Mimura T. [A case of rheumatoid arthritis complicated with deteriorated interstitial pneumonia after the administration of abatacept]. *Nihon Rinsho Meneki Gakkai Kaishi*. 2012;35(5):433-8.

Weinblatt ME, Moreland LW, Westhovens R, Cohen RB, Kelly SM, Khan N, et al. Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial program. *The Journal of rheumatology* [Internet]. 2013; 40(6):[787-97 pp.]. Available from: <http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/715/CN-01123715/frame.html>.

Nakashita T, Ando K, Takahashi K, Motojima S. Possible effect of abatacept on the progression of interstitial lung disease in rheumatoid arthritis patients. *Respir Investig*. 2016;54(5):376-9.

Fernández Díaz C LJ, Castañeda S, Ojeda-García C, Olivé A, Carreira PE, et al. . Abatacept in rheumatoid arthritis with interstitial lung disease: a multicenter study of 55 patients [abstract]. *Arthritis Rheumatol* 2016;68 (Suppl S10): 2583.